RecruitingPhase 1NCT07708116

First in Human Trial of CTX-187 in Healthy Volunteers and Chronically Infected Patients

A Phase 1 First-In-Human, Double-Blind, Single and Multiple Ascending Dose Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravenous Doses of CTX-187 in Healthy Volunteers Followed by Multiple Doses in Patients With a Bacterial Infection

Sponsor

Centauri Therapeutics Limited

Enrollment

104 participants

Start Date

Jun 16, 2026

Study Type

INTERVENTIONAL

Conditions

Bacterial Infections Bronchiectasis Adult Bronchiectasis With Pseudomonas Aeruginosa Colonization

Summary

The primary objective of this trial is to assess the safety and tolerability of single and multiple ascending intravenously (IV) infused doses of CTX-187 when administered to healthy adult male and female participants and participants with a bacterial infection (bronchiectasis participants chronically infected with P. aeruginosa).

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called CTX-187 and a drug called Placebo for people with bacterial infections, bronchiectasis adult, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.